KRAS G12A

Kras G12A与eGFR T790M一样，已被证明能够在肺腺癌中增强对酪氨酸激酶抑制剂的获得性抵抗。
KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.